Delta Lloyd’s Alnylam Pharmaceuticals ALNY Stock Holding History

Delta Lloyd’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,204	Closed	-$353K	–	433
2016 Q3	$353K	Hold	5,204	–	–	0.01%	635
2016 Q2	$289K	Hold	5,204	–	–	0.01%	641
2016 Q1	$327K	Hold	5,204	–	–	0.01%	631
2015 Q4	$490K	Hold	5,204	–	–	0.02%	568
2015 Q3	$418K	Hold	5,204	–	–	0.01%	617
2015 Q2	$624K	Buy	+5,204	New	+$622K	0.02%	504

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Delta Lloyd's ALNY Position: Q4 2016 in Review

Delta Lloyd sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 5,204 shares — an estimated $353K sold.

Delta Lloyd first reported a position in ALNY in Q2 2015 and held it in 6 quarters. The position peaked at $624K in Q2 2015. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

Delta Lloyd reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Delta Lloyd sold 5,204 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $353K.
Delta Lloyd first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Delta Lloyd's Alnylam Pharmaceuticals position peaked at $624K in Q2 2015.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Delta Lloyd's 13F filing for Q4 2016, filed 2 Feb 2017.